BP are interested in seeing efficacy which is already seen early in Ph1 clinical trial for VAXINIA. IMU spent $17M last quarter and are looking at further cost reduction, they have $45M in cash start of this year and have access to $46M in CN and warrant and around $20M from last year's R&D rebate. So likely IMU will have $50M in cash at the start of 2026 provided the CN and warrant are converted and exercise.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.002(10.7%) |
Mkt cap ! $93.33M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $167.5K | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 54 | 14898285 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 7352178 | 24 |
View Market Depth
| Last trade - 14.09pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |